Featured Oncology NewsEU Green Light For Roche’s Tecentriq
September 25, 2017
FDA Grants Accelerated Approval To Pembrolizumab For Advanced Gastric Cancer
September 25, 2017
Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontellitrac and a customized email alert system summarizing the most recent oncology-specific information available.
The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.
Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma
New Data for Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma
Myriad Genetics Announces Positive Data Supporting New riskScore™ Test at the 36th Annual Conference of the National Society of Genetic Counselors
Pipeline Online is the most comprehensive and up to date oncology pipeline information resource that is widely available on the web ...
OBR Finance tracks the market performance of oncology companies and products, and compares our performance versus other indices ...
OBR Radar is a snapshot of upcoming pivotal events in the oncology industry such as FDA action dates, anticipated announcement of pivotal clinical data, and ODAC dates ...
[via telephone or webcast]
[via telephone or webcast]
Buenos Aires, Argentina
Morgantown, WV
[via telephone or webcast]
San Francisco, CA
[via telephone or webcast]
Thompsonville, MI
Barcelona, Spain
Nashville, TN
[via telephone or webcast]
[via telephone or webcast]
[via telephone or webcast]
Richmond, VA
[via telephone or webcast]
Barcelona, Spain
Singapore
Geneva, Switzerland
Atlanta, GA
[via telephone or webcast]
San Francisco, CA
San Francisco, CA
Amsterdam, The Netherlands
San Francisco, CA
Washington, D.C.
Chicago, IL
Amsterdam, The Netherlands
Phoenix, AZ
Phoenix, AZ
Featured Content
Previous
News Story Commentary
Meet the Editorial BoardView all Commentary
FDA Approves Amgen And Allergan's MVASI™ (bevacizu...
September 15th 2017 by Howard S. Hochster, MD
First approval for a biosimilar in solid tumor usage! This should help bring down the cost of bev ...
Read More
Roche Presents Data From Global Phase III Study Show...
September 08th 2017 by H. Jack West, MD
The results of the ALUR trial are impressive but not surprising at all. We should expect a second ...
Read More
At $475,000, New Cancer Drug Raises Thorny Questions...
September 05th 2017 by Thomas Marsland, MD
WOW...that is a hunk of change...BUT it would appear that Novartis is at least following some of th...
Read More
Sneak Peek Into the ESMO 2017 Press Program
August 30th 2017 by Howard (Jack) West, MD
FLAURA was added to the meeting and press program after I wrote these comments. We will still need ...
Read More
A Cancer Conundrum: Too Many Drug Trials, Too Few Pa...
August 17th 2017 by Thomas Marsland, MD
So I actually had the chance to read this article in the Sunday Times while traveling (am usually ...
Read More
Sneak Peek Into the ESMO 2017 Press Program
August 14th 2017 by H. Jack West, MD
It appears that while the PACIFIC trial of durvalumab consolidation after chemoradiation is being p...
Read More
OBR Green